Product Description
Oxiglutatione is the oxidized disulfide form of glutathione (GSH) with potential protective activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxiglutatione)
Mechanisms of Action: Free Radical Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cellectar Biosciences
Company Location: FLORHAM PARK NJ 07932
Company CEO: JAMES V. CARUSO
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Ovarian Cancer|Preleukemia|Myelodysplastic Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ND | P3 |
Completed |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2010-01-07 |
|
NOV002-C301 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2010-01-01 |
31% |
NOV002- IS21 -OC | P2 |
Completed |
Ovarian Cancer |
2008-05-01 |
|
NCT00960726 | P2 |
Withdrawn |
Preleukemia|Myelodysplastic Syndrome |
None |